Gunderson Dettmer Advises Tarsus Pharmaceuticals On $115.0 Million Public Offering

March 1, 2024Client News

Gunderson Dettmer represented client Tarsus Pharmaceuticals, a biopharmaceutical company, in its $115.0 million public offering. Tarsus is advancing its pipeline to address several diseases with high unmet need across a range of therapeutic categories, including eye care, dermatology and infectious disease prevention. The company offered and sold $115.0 million of common stock and pre-funded warrants.

Goldman Sachs & Co. LLC, BofA Securities, Guggenheim Securities, LLC and Oppenheimer & Co. acted as joint book-running managers for the offering.

The Gunderson Dettmer deal team was led by Ryan Gunderson and included Daniel Reichert, Leanne Gould, and Ben Cohen-Kurzrock.

Tarsus Pharmaceuticals